Diagnósticos da América (DASA3) investor relations material

Executive summary

• Achieved consistent growth in Q1 2026, with improvements in revenue, margin, and volume, reflecting structural initiatives, strategic repositioning, and operational efficiency gains.

• Net income reached R$9 million, reversing a R$111 million loss in 1Q25, driven by operational improvements and lower financial expenses.

• Organizational simplification, disciplined capital allocation, and digitalization initiatives enhanced efficiency and predictability.

• Maintained strong national platform and leadership in diagnostics in Latin America, with scalable infrastructure and leading brands.

• Rede Américas joint venture progressing as planned, with synergy capture and asset management reinforcing medium- and long-term value creation.

Financial highlights

• Consolidated gross revenue reached R$2.4 billion, up 14% year-over-year (Current Scope); diagnostics revenue up 15.3%, hospitals and oncology up 2.1%.

• Consolidated EBITDA was R$573 million, up 28% year-over-year, with margin expanding by 2.7 p.p. to 25.8%.

• Net income was R$9 million, reversing a R$111 million loss in 1Q25.

• Free cash flow improved by R$101 million year-over-year, with operating cash generation of R$21 million and free cash flow of R$5 million.

• Rede Américas reported gross revenue of R$3.4 billion, EBITDA of R$438 million (14.2% margin), and net income of R$38 million.

Outlook and guidance

• Expect robust free cash generation in 2026, with continued focus on core diagnostics, cost control, digitalization, and operational efficiency.

• Premium and home care segments expected to outpace general market growth; B2B and digital channels remain key drivers.

• Second quarter anticipated to be weaker due to calendar effects, including the World Cup.

• Management prioritizes high-return projects and strategic asset preservation, monitoring impacts of Brazil's tax reform and international tax changes.